A study to evaluate the immune health benefits of two selected probiotic strains

Completed

• Conditions: General immune defence; Signs and Symptoms; Immune defence

• Registration Number: ISRCTN64739181
• Lead Sponsor: Chr. Hansen A/S (Denmark)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-12-23
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

1. Healthy male and female subjects
2. Aged 20 - 60 years old

Exclusion Criteria

1. Presence of acute or terminal disease
2. Gastrointestinal disorders or surgery
3. Intolerance for milk protein or lactose
4. Daily consumption of probiotic products
5. Antibiotic treatment
6. Any vaccination 15 days prior to baseline
7. Prior influenza vaccination for the 2008/2009 season
8. Already having suffered from influenza during the 2008/2009 season

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Antigen-specific response to the influenza vaccination in plasma and saliva 4 weeks after the vaccination.

Secondary Outcome Measures

Name	Time	Method
General adaptive and innate immune responses to the influenza vaccination 4 weeks after the vaccination.